Drugs aimed at ERBB2, FCGR3A, and FLT3 are primarily used in treating various cancers and benign tumors, while ALDH2 is targeted in therapies for a range of systemic diseases, notably cancer and substance dependence. Here, ALDH2 is linked to benign neoplasm.